Source: CENTR Brands.
  • CENTR (CNTR) is reporting a U.S. retail presence of 3,050 stores as of February 2022
  • The figure represents a 69.4-per-cent growth rate since November 2021
  • The company expects continued growth as it rolls out new experiential branding programs
  • CENTR Brands is a North American functional beverage company
  • CENTR (CNTR) is up by 4 per cent trading at $0.78 per share

CENTR (CNTR) is reporting a U.S. retail presence of 3,050 stores as of February 2022.

The figure is up 24.5 per cent since January and represents a 69.4-per-cent growth rate since November 2021.

Growth in Q1 is underlined by Brightfield Research’s recent report naming CENTR the #1 CBD beverage in the U.S. 

“CENTR is well-positioned to achieve another banner year of growth this year,” said David Young, CENTR’s CFO. “In addition to our retail expansion, CENTR is rolling out exciting new branding programs that will develop even greater connections with our growing customer base.”

“As CENTR’s retail footprint grows, these experiential and brand-oriented programs should further stimulate sales velocity at existing locations, expanding CENTR’s market penetration in a fast-growing category,” he added.

Young recently spoke with Brieanna McCutcheon about the company.

CENTR Brands is a North American functional beverage company. Its products include CENTR, CENTR Sugar Free and CENTR Instant.

CENTR (CNTR) is up by 4 per cent trading at $0.78 per share as of 1:40 pm EST.

More From The Market Online

Odd Burger to add 40 locations in Florida

Odd Burger (TSXV:ODD) will develop 40 new locations in Florida over the next eight years, with its sights set on further U.S. expansion.

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.